8-K filing — Atkore Inc. (ATKR)
Filed: 2026-09-15 AccNo: 0001666138-26-000027 Size: 182 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
This Walmart Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts changed ratings for ATKR, CI, NKE, WMT, and OLN. See how they view these stocks and consider buying WMT.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?
CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services (BTSG) reported strong Q2 2026 results with Specialty and Infusion revenue growing 30% and scripts rising 31%, driven by branded limited distribution drugs (LDDs) and expansion into rare and orphan therapies. The company added two new LDDs, bringing its portfolio to 155 programs with 12 launched in 2026. Pharmacy Solutions adjusted EBITDA increased 44% to $180 million. Peers Cigna and Humana also showed strength in specialty pharmacy segments, though with different growth drivers.
Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
Nike (NKE) Registers a Bigger Fall Than the Market: Important Facts to Note
Nike stock fell 1.21% on September 16, 2026, underperforming the S&P 500's 0.45% decline. The company has depreciated 9.59% over the past month. Upcoming Q1 earnings (October 1) are expected to show a 10.2% EPS decline year-over-year to $0.44, with revenue projected at $11.43 billion, down 2.51%. Nike holds a Zacks Rank of #4 (Sell) and trades at a Forward P/E of 21.47, above its industry average of 13.64.